Objectives: We have shown that the routine use of a multiple decontamination regimen with oropharyngeal and digestive polymyxin/tobramycin/amphotericin B plus mupirocin/chlorhexidine in intubated patients reduced all-cause acquired infections (AIs) in the intensive care unit (ICU). We now assessed the long-term impact of this strategy on AIs involving multidrug-resistant aerobic Gram negative bacilli (AGNB) and acquired episodes of extended-spectrum betalactamase (ESBL)-producing Enterobacteriaceae rectal carriage.
Highlights
-We assessed the long-term impact of decontamination on MDR AGNB acquired infections -AIs and colonization rates were prospectively recorded -The incidence rate of multidrug-resistant AGNB AIs substantially declined with time -ESBL-producing Enterobacteriaceae acquired rectal carriage also declined -Multiple decontamination did not favor the emergence of antimicrobial-resistant AGNB
INTRODUCTION
Infections acquired in the Intensive Care Unit (ICU) account for substantial morbidity and hospital costs (1) and increase the risk of death in ICU (2) . Selective decontamination of the digestive tract has been recognized as an effective measure to control infections in the ICU with high-quality evidence (3) . Many protocols using various antimicrobial agents or antiseptics have been used for many decades. Selective digestive decontamination (SDD) using oropharyngeal and digestive topical colistin, tobramycin and amphotericin B with 4-day systemic cefotaxime reduced respiratory infections (4), bloodstream infections (5) and, more importantly, the mortality rate (odds ratio [OR] for death at day 28 = 0.83 [95% CI, 0.72 -0.97]) compared with standard care (5) . Selective oropharyngeal decontamination (SOD) using the same topical antibiotics in the oropharynx also reduced bloodstream infections and decreased mortality rate (OR=0.86 [0.74 -0.99]) (5) . A combination of oropharyngeal and digestive colistin/tobramycin with mupirocin and chlorhexidine body wash has been shown to reduce all-cause infections in intubated patients (6) .
However, the impact on the emergence of multi-drug resistant bacteria is unclear. A recent meta-analysis detected no relationship between the use of SDD or SOD and the development of antimicrobial resistance in pathogens in ICU patients and noted that this problem was understudied (7) . The prevalence of rectal carriage of aminoglycoside-resistant AGNB increased during the use of SOD and SDD, although the consequence on infections was not shown (8) . The use of topical polymyxin/tobramycin/amphotericin B plus mupirocin/chlorhexidine in intubated patients was associated with the reduction of all-cause ICU-acquired infections including multidrug-resistant AGNB in all patients (9) . In order to detect the emergence of multidrug-resistant organisms, we assessed the rates of acquired infections (AIs) caused by microorganisms resistant to antibiotics and rectal carriage of extended-spectrum β-lactamase (ESBL)-producing AGNB over a 5-year period with this regimen.
METHODS AND PATIENTS

Surveillance of antimicrobial-resistant microorganisms
Surveillance of total AIs was performed prospectively in our ICU as reported previously (9) (10) (11) . The definitions used were those of the Centers for Disease Control and Prevention (12) modified with the new definitions of the French National Technical Committee for Nosocomial Infection (available at http://www.sante.gouv.fr/IMG/pdf/rapport_complet.pdf). For the purpose of this study, pneumonia was diagnosed on a clinical and radiologic basis and was confirmed by a positive culture of a bronchoalveolar lavage (>10 3 CFU/ml) or an endotracheal aspiration (≥10 5 CFU/ml). Infections were considered to be acquired in the ICU when they were diagnosed after 48 hours and if patients were not incubated at the time of admission. Antibiograms were performed on all clinical samples. Methicillin resistance was determined on all
Staphylococcus aureus isolates and vancomycin resistance on all Enterococcus sp. isolates.
Special attention was paid to the resistance to 3rd-generation cephalosporins, aminoglycosides, carbapenems, fluoroquinolones and colistin in AGNB.
Universal ESBL-producing Enterobacteriaceae screening was performed on rectal swabs taken at admission, discharge and once a week during the ICU stay. Samples were directly inoculated onto antibiotic selective agar (chromID BLSE agar®, bioMérieux, Marcy l'Etoile, France) (13) . The diffusion method for antimicrobial susceptibility testing was systematically executed on growing oxidase negative colonies. The ESBL resistance mechanism was phenotypically confirmed by the existence of a synergy between a thirdgeneration cephalosporin and clavulanate using the double-disk synergy test or ESBL Etests® (bioMérieux, Marcy l'Etoile, France) (14) . Contact precautions were applied to the patients who were screened positive and maintained during the entire ICU stay or until the negative results of two consecutive weekly samples. An episode of acquired colonization was defined as the acquisition during the ICU stay of a new ESBL-producing AGNB, whether the patient was not colonized or colonized with a different ESBL-producing species on a prior sample.
Due to multiple epidemic ESBL-producing AGNB species (mostly Klebsiella sp.,
Enterobacter sp. or Citrobacter sp.), more than one episode per patient could be recorded.
Screening for methicillin-resistant S aureus (MRSA) and vancomycin-resistant enterococci (VRE) was not a routine procedure.
Prevention of healthcare-associated infections in the ICU
The Guidelines of the French Society for Hospital Hygiene were applied for the prevention of ICU-acquired infections (available at http://www.sf2h.net/publications-SF2H/SF2H_surveiller-et-prevenir-les-IAS-2010.pdf). Hand rubbing with hydroalcoholic solutions was implemented as standard care. Chlorhexidine was used for skin disinfection.
Procedures for the maintenance of indwelling catheters and the management of intubated patients were applied according to institutional care bundles.
Decontamination was applied to intubated patients who were expected to require intubation for 24 hours or more. The protocol has been reported elsewhere (9) and consisted of oral suspension of colistin, tobramycin and amphotericin B administered in the oropharynx and the gastric tube four times daily and one course of nasal mupirocin and chlorhexidine gluconate body washing twice daily during the period of intubation plus 24 hours. The patients who were not intubated received standard care. This protocol was implemented from
June 2007 and has continued uninterrupted. In patients who had any sample positive for an AGNB resistant to both tobramycin and colistin, oropharyngeal and digestive topical antimicrobials were discontinued and replaced by oropharyngeal rinse with chlorhexidine 0.12% 5 ml four times daily. The administration of mupirocin and chlorhexidine body washing were maintained.
Study design
We previously reported a strong decline in AIs during a 1-year period following the implementation of our multiple-site decontamination protocol compared to the previous 1-year period without decontamination (9) . Because 1-year surveillance may have been too short to detect a significant emergence of resistant bacteria, we continued the surveillance over a longer period of time. 
Endpoints
The surveillance study focused on the resistance of AGNB to seven antimicrobials:
ceftazidime, imipenem, ciprofloxacin, gentamicin, tobramycin, amikacin and colistin.
Multidrug resistance in AGNB was defined as the resistance to 2 or more among the following antibiotics: third-generation cephalosporins, imipenem, all three aminoglycosides and ciprofloxacin. Based on positive clinical cultures which were sampled at the time of the patients's admission (from 48 hours before to 24 hours after), we assessed the prevalence of AGNB which were resistant to at least one antibiotic at admission per 100 admissions. The main endpoint was the incidence rates of ICU-attributable AIs caused by multidrug-resistant AGNB. We also studied the incidence rates of AIs caused by Enterobacteriaceae,
Pseudomonas aeruginosa and other glucose-nonfermenting GNB resistant to each antibiotic separately, because the detection of increased resistance to one of these antimicrobials would be a relevant finding as well. First, the incidence rates of AIs during the entire study period were compared to those previously reported during a 1-year pre-intervention period without decontamination (9) . Then, trends throughout the 10 study semesters were investigated. As secondary endpoints, the acquisition of colonization with ESBL-producing AGNB and with colistin-resistant ESBL-producing AGNB in the ICU was assessed during the study period.
Lastly, the incidence rate of total AIs (distinguishing Gram-positive cocci, GNB and fungal AIs) and the consumption of five broad-spectrum antibiotics and hydroalcoholic solutions were also evaluated.
Statistical analysis
Statistical analysis was performed using SAS 9.4 for Windows (SAS Institute, Cary, NC, USA). Quantitative variables are expressed as the median (25 th percentile-75 th percentile), and comparisons between groups were performed using a Kruskall-Wallis test.
Categorical variables were compared with a chi-square test. Incidence rates were analyzed with a Poisson regression model. The trend analysis of multidrug-resistant AGNB infections and total infections was adjusted for the following risk factors: the presence of urinary catheter ≥3 days, intubation ≥3 days, central venous catheter ≥1 day, Simplified Acute Physiology Score II (SAPSII) greater than 25 and diagnosis with a high risk AI (digestive, trauma categories) at admission (9) . An odds ratio (OR) greater than 1 indicated an increase with each semester, and an OR lower than 1 indicated a decrease. Trends for categorical variables were analyzed by logistic regression. All tests were two sided, and a p value of less than or equal to 0.05 was considered statistically significant.
RESULTS
Report of bacteremia due to resistant microorganisms in our Hospital
The proportion of bacteremia due to resistant organisms was used to assess the general level of antimicrobial resistance in our Institution ( Table 1 ). The proportion of S. aureus bacteremia due to MRSA varied between 20% and 26% depending on the year, and did not significantly change with time, especially in the non-ICU wards (p for trend 0.09). For enterococci, the proportion of VRE was lower than 5%, whether in ICU or outside ICU. Ceftazidime resistance rate for P. aeruginosa bacteremia averaged 3% in the non ICU wards. In contrast,
there was a significant increase with time in the rate of ESBL-producing Enterobacteriaceae outside ICUs from 3% to 7% (p=0.003).
Characteristics of the patients at admission, device exposition and outcome
During the study period, there were some differences in patients' demographic characteristics and diagnosis categories across semesters, reflecting temporal variability in recruitment. The use of a central venous catheter and urinary catheter, but not intubation, tended to increase significantly over time (details in Supplemental digital content, eTable 1 and legend). Although mortality in ICU tended to decrease during the ten semesters of the study (adjusted OR=0.96 [0.93-0.99], p=0.02; adjustment for the Glasgow coma score, SAPSII, the category of diagnosis, the presence of infection at admission and the use of invasive devices), the overall rate (15.0%) did not differ from the ICU mortality rate during the pre-intervention period (14.4%, p=0.61; eTable 1).
Prevalence of antimicrobial resistant AGNB at admission
Based on positive clinical cultures, the prevalence rate at admission of AGNB resistant to at least one of the marker antimicrobials was 3.2 per 100 admissions during the preintervention period and 3.5 per 100 admissions during the study period (p=0.71). During the study semesters, there was no change in the prevalence rate of AGNBs resistant to each antimicrobial, multidrug-resistant or ESBL-producing (p for trend ≥ 0.30 for all analyses, Table 2 ). By contrast, the overall rate of rectal colonization with ESBL-producing AGNB was 4.5 per 100 admissions and tended to increase with time with a peak at 7.6% during the 8 th semester (p for trend =0.03; Supplemental digital content, eTable 1).
Acquired infections caused by multidrug-resistant AGNB
The numbers (incidence rates) of ICU-attributable AIs involving antimicrobial resistant organisms and episodes of acquired rectal colonization with ESBL-producing AGNB are detailed in the Supplemental digital content, eTable 2. Of 206 AIs involving AGNB, 63
(30.6%) were caused by multidrug-resistant AGNB.
Comparison with the pre-intervention period. The incidence rates of AIs involving multidrugresistant AGNB, by semester, are represented in Figure 1 . 
Acquired rectal colonization and infection with ESBL-producing AGNB
The incidence rate of ESBL-producing AGNB acquisition episodes significantly declined with time (p=0.04, (Table 4) .
Total AIs, use of antibiotics and hydroalcoholic solution
There was a significant trend towards a decline in total AIs and AIs involving AGNB, irrespective of antimicrobial resistance over the study period (Table 5 ). In contrast, AIs involving Gram-positive cocci remained stable. There was no infection caused by vancomycin-resistant Enterococcus. The consumption of five broad-spectrum antibiotics mostly used for the treatment of healthcare-associated infections was studied for each study semester ( Figure 2 ). There was a gradual increase in the use of piperacillin/tazobactam (trend:
p<0.0001), stability in the use of vancomycin, (p=0.7783) and a significant decrease in the use of ciprofloxacin, amikacin, carbapenems, and the five antimicrobials taken altogether (all pvalues<0.0001). On average, the use of hydroalcoholic solution for hand disinfection was 116 liters per 1,000 patient-days and did not significantly vary over 5 years (p=0.07, supplemental digital content, eFigure 1).
DISCUSSION
We performed a longitudinal study over 5 years to detect the emergence of multidrugresistant organisms. The main result was the strong decline in the incidence rate of multidrug resistant AGNB, which was observed with time in our ICU, with the lowest rates in the last four semesters. This could not be explained by a simultaneous decline in the prevalence of resistant AGNB at admission not over the same time period.
No consensus has yet been reached on the definition of "multidrug resistance". The interim definitions proposed were non-susceptibility to at least one agent in three or more antimicrobial categories, including penicillins (15) . Resistance to all agents of the same category did not change the classification. We used the same definitions of multiresistance as in a previous publication (9) . In AGNB clinical isolates, we observed that the resistance to either third-generation cephalosporins or imipenem was always associated with the resistance to either one broad-spectrum penicillin or one aminoglycoside, and the resistance to both ciprofloxacin and aminoglycosides was also associated to non-susceptibility to at least one broad-spectrum penicillin. Thus, our definition of multidrug resistance was close to the definitions proposed by the international expert panel, except for the resistance to all aminoglycosides in our criteria.
We also studied AIs caused by organisms resistant to any of 7 antimicrobials separately. Regarding AIs involving resistant Enterobacteriaceae, a similar trend was uniformly observed with any antimicrobial except for imipenem resistant organisms due to the low number of AIs (only 4 during the first four semesters). For AIs involving P.
aeruginosa, the declining trend was observed for the resistance to imipenem and tobramycin.
AIs involving P aeruginosa resistant to ceftazidime, amikacin or colistin were rare. Similarly, AIs caused by other glucose-nonfermenting AGNB were infrequent and did not vary throughout the study period.
The level of antimicrobial resistance of AGNB was not particularly low during this 5-year period. The proportion of patients colonized with ESBL-producing AGNB, when colonization at admission and acquisition in ICU were combined, was 6.6% (3.9 to 8.8%
depending on semesters), consistent with other reports in Europe (16) (17) (18) and in the USA (19) .
Colistin-resistant ESBL-producing K. pneumoniae isolates were identified mostly in rectal samples, as reported in the Dutch experience (20, 21) , but no epidemic diffusion was observed. In contrast, the incidence rates of AIs caused by ESBL-producing Enterobacteriaceae were low and declining. Third-generation cephalosporins-resistant Enterobacteriaceae isolates were mostly Enterobacter, Citrobacter, Serratia spp., which exhibited a cephalosporinase hyperproduction phenotype. Overall, the incidence of AIs involving third-generation cephalosporin-resistant Enterobacteriaceae declined steadily.
The reduction in the use of antimicrobials was in accordance with previous studies.
Compared with standard care, a substantial decrease in the consumption of carbapenems and quinolones (mostly ciprofloxacin) was shown (5, 22) . In our study, the increased use of piperacillin/tazobactam did not compensate the important decrease in the use of carbapenems, ciprofloxacin and amikacin. A reduction in the use of carbapenems and quinolones was encouraged by the antibiotic stewardship bundle in our hospital. The development of antibiotic resistance in AGNB respiratory isolates has been shown to be mostly associated with systemically administered antibiotics, especially carbapenem use, but similar between selective decontamination and standard care (23).
The decline in the incidence of colonization or infection with antibiotic resistant AGNB is in accordance with other data reporting the use of SDD, SOD or derived decontamination protocols. A meta-analysis of 64 studies failed to demonstrate that SDD or SOD was associated with more infections or higher carriage rates with multidrug-resistant organisms in patients who received these interventions. Interestingly, there was a reduction in polymyxin-resistant AGNB (OR=0·58, 0·46-0·72; p<0.0001), third-generation cephalosporin-resistant AGNB (0·33, 0·20-0·52; p<0.0001) and a trend toward reduction of aminoglycoside-resistance (0·73, 0·51-1·05; P=0.09) in recipients of selective decontamination compared with those without intervention (7) . Similarly, longitudinal analysis of the antibiotic susceptibilities of respiratory tract isolates from 38 Dutch ICUs revealed a significant decline in antibiotic resistance in those ICUs that introduced SDD or SOD, as well as a trend toward decreasing resistance during its use (24) .
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Preintervention
Legend of Figure 1 The two pre-intervention semesters represented group A in a previous study (9) . The implementation period was from June to December 2007. S1, S2,… to S10 denote 1st semester, 2nd semester, … to 10th semester.
Legend of Figure 2 . S1, S2,…,S10 denote 1st semester, 2nd semester,…, 10th semester.
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